Prediction of pulmonary complications and long-term survival in systemic sclerosis

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1625-1635

  Nihtyanova, Svetlana I ^a   Schreiber, Benjamin E ^a   Ong, Voon H ^a   Rosenberg, Daniel ^b   Moinzadeh, Pia ^c   Coghlan, J Gerrard ^a   Wells, Athol U ^d   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARBON MONOXIDE; CENTROMERE ANTIBODY; CREATININE; DNA TOPOISOMERASE ANTIBODY; ENZYME ANTIBODY; HEMOGLOBIN; RIBONUCLEOPROTEIN ANTIBODY; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE DURATION; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LONG TERM SURVIVAL; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; OVERALL SURVIVAL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; SEX DIFFERENCE; SMOKING; SYSTEMIC SCLEROSIS;

ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY FIBROSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TIME FACTORS; VITAL CAPACITY;

EID: 84898775777     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38390     Document Type: Article

References (50)

1. Steen VD, Medsger TA,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
2. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y,. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51: 1017-26.
3. Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP,. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109-15.
4. Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Schuerwegh A, et al. High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis [abstract]. Arthritis Rheum 2012; 64: 4167.
5. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
6. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.
7. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-60.
8. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-30.
9. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940-6.
10. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14: R213.
11. Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A,. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011; 40: 127-32.
12. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
13. Vonk MC, Broers B, Heijdra YF, Ton E, Snijder R, van Dijk AP, et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009; 68: 961-5.
14. Kuo CF, See LC, Yu KH, Chou IJ, Tseng WY, Chang HC, et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011; 40: 373-8.
15. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15: 102-9.
16. Hashimoto A, Endo H, Kondo H, Hirohata S,. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22: 272-9.
17. Beretta L, Santaniello A, Cappiello F, Chawla NV, Vonk MC, Carreira PE, et al. Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. Clin Exp Rheumatol 2010; 28: S18-27.
18. Domsic RT, Nihtyanova S, Wisniewski SR, Fine MJ, Kwoh CK, Denton CP, et al. External validation of a two-year mortality risk prediction rule in early diffuse systemic sclerosis patients [abstract]. Arthritis Rheum 2012; 64 Suppl: S299-300.
19. Assassi S, del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009; 61: 1403-11.
20. Komocsi A, Vorobcsuk A, Faludi R, Pinter T, Lenkey Z, Kolto G, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies [review]. Rheumatology (Oxford) 2012; 51: 1027-36.
21. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
22. Bryan C, Howard Y, Brennan P, Black C, Silman A,. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35: 1122-6.
23. Hissaria P, Lester S, Hakendorf P, Woodman R, Patterson K, Hill C, et al. Survival in scleroderma: results from the population-based South Australian Register. Intern Med J 2011; 41: 381-90.
24. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
25. Joven BE, Almodovar R, Carmona L, Carreira PE,. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39: 285-93.
26. Kim J, Park SK, Moon KW, Lee EY, Lee YJ, Song YW, et al. The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol 2010; 29: 297-302.
27. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-67.
28. Hashimoto A, Tejima S, Tono T, Suzuki M, Tanaka S, Matsui T, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011; 38: 1931-9.
29. Domsic RT, Medsger TA,. Disease subsets in clinical practice. In:, Varga J, Denton CP, Wigley FM, editors. Scleroderma: from pathogenesis to comprehensive treatment. New York: Springer; 2012. p. 45-52.
30. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788-92.
31. Bryan C, Knight C, Black CM, Silman AJ,. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-5.
32. Steele R, Hudson M, Lo E, Baron M, on behalf of the Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 519-24.
33. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A,. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-40.
34. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al, EUSTAR Co-authors. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
35. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008; 158: 487-95.
36. Hanke K, Dahnrich C, Bruckner CS, Huscher D, Becker M, Jansen A, et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009; 11: R28.
37. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 318-26.
38. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada-Y-Martin RM, Draeger H, et al, and the GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
39. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al, and the ItinerAIR-Sclerodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-9.
40. Steen V, Medsger TA Jr., Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
41. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-8.
42. Meune C, Avouac J, Airo P, Beretta L, Dieude P, Wahbi K, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63: 2790-6.
43. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-91.
44. Tormey VJ, Bunn CC, Denton CP, Black CM,. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001; 40: 1157-62.
45. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr., Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60: 1112-8.
46. Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335-42.
47. Seibold JR, Denton CD, Grunig E, Bonderman D, Distler O, Khanna D, et al. An evidence-based screening algorithm for pulmonary arterial hypertension in systemic sclerosis [abstract]. Arthritis Rheum 2012; 64 Suppl: S371-2.
48. Hudson M, Mahler M, Pope J, You D, Tatibouet S, Steele R, et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012; 39: 787-94.
49. Sandqvist G, Scheja A, Hesselstrand R,. Pain, fatigue and hand function closely correlated to work ability and employment status in systemic sclerosis. Rheumatology (Oxford) 2010; 49: 1739-46.
50. Singh MK, Clements PJ, Furst DE, Maranian P, Khanna D,. Work productivity in scleroderma: analysis from the University of California, Los Angeles Scleroderma Quality of Life Study. Arthritis Care Res (Hoboken) 2012; 64: 176-83.